Mercado de terapias con exosomas en América del Norte: tendencias de la industria y pronóstico hasta 2028

Solicitud de índiceSolicitud de índice Hable con el analistaHable con el analista Comprar ahoraComprar ahora Consultar antes de comprarConsultar antes Informe de muestra gratuitoInforme de muestra gratuito

Mercado de terapias con exosomas en América del Norte: tendencias de la industria y pronóstico hasta 2028

  • Medical Devices
  • Published Report
  • Dec 2021
  • North America
  • 350 Páginas
  • Número de tablas: 83
  • Número de figuras: 49

North America Exosome Therapeutic Market

Tamaño del mercado en miles de millones de dólares

Tasa de crecimiento anual compuesta (CAGR) :  % Diagram

Diagram Período de pronóstico
2021 –2028
Diagram Tamaño del mercado (año base)
USD 327.63 Thousand
Diagram Tamaño del mercado (año de pronóstico)
USD 1,140.63 Thousand
Diagram Tasa de crecimiento anual compuesta (CAGR)
%
Diagram Jugadoras de los principales mercados
  • Dummy1
  • Dummy2
  • Dummy3
  • Dummy4
  • Dummy5

>Mercado de terapias con exosomas en América del Norte, por tipo (exosomas naturales, exosomas híbridos), fuente (células madre mesenquimales, sangre, fluidos corporales, orina, células dendríticas, saliva, leche y otros), fuente (linfocitos T y otros), terapia (inmunoterapia, terapia génica, quimioterapia), capacidad de transporte (biomacromoléculas y moléculas pequeñas), aplicación (trastornos metabólicos, oncología, trastornos cardíacos, neurología, trastornos inflamatorios, trasplante de órganos, trastornos ginecológicos, trastornos sanguíneos y otros), vía de administración (parenteral, oral), usuario final (institutos de investigación y académicos, hospitales y centros de diagnóstico), por país (EE. UU. y México), tendencias del mercado y pronóstico hasta 2028.  

Mercado de terapias con exosomas en América del NorteAnálisis y perspectivas del mercado: mercado de terapias con exosomas en América del Norte

Se espera que el mercado de terapias con exosomas de América del Norte gane crecimiento de mercado en el período de pronóstico de 2022 a 2029. Data Bridge Market Research analiza que el mercado está creciendo con una CAGR del 17,2% en el período de pronóstico de 2021 a 2028 y se espera que alcance los USD 1.140,63 mil para 202 desde USD 327,63 mil en 2021. Es probable que la creciente prevalencia de enfermedades autoinmunes inflamatorias crónicas y los avances tecnológicos en la terapia con exosomas sean los principales impulsores que impulsen la demanda del mercado en el período de pronóstico.

Los exosomas son una clase específica de vesículas extracelulares derivadas de células compuestas de endosomas y tienen típicamente entre 30 y 150 nm de diámetro, el tipo más pequeño de vesícula extracelular. Protegidos por una bicapa lipídica, los exosomas son empujados hacia el entorno extracelular, que contiene una carga compleja de contenidos derivados de la célula original. Los contenidos presentes en la carga son proteínas, lípidos, ácido ribonucleico mensajero (ARNm), ácido ribonucleico microsomal (miARN) y ácido desoxirribonucleico (ADN). Los exosomas se distinguen por cómo se forman: a través de la fusión y exocitosis de cuerpos multivesiculares en el espacio extracelular. Los exosomas se han relacionado con el tratamiento de diversas enfermedades crónicas, como los trastornos autoinmunes. La nanotecnología ha mostrado nuevos conocimientos para la detección previa del cáncer basada en nanotransportadores como los exosomas. Dado que los exosomas ofrecen un gran potencial de aplicación en intervenciones terapéuticas, se los ha considerado como posibles portadores de fármacos.

Los exosomas se dividen en dos tipos: los exosomas naturales y los exosomas híbridos. Los exosomas naturales se subdividen en exosomas exógenos y exosomas autólogos. Los exosomas autólogos son vehículos seguros y eficaces para la administración dirigida de fármacos para el tratamiento del cáncer, enfermedades autoinmunes y enfermedades inflamatorias crónicas. Los exosomas exógenos son pequeñas vesículas de membrana extracelular liberadas por los endosomas de varias células y se pueden encontrar en la mayoría de los fluidos corporales, como el líquido sinovial, el líquido amniótico y el semen. En el cáncer, los exosomas tienen funciones vitales en la propagación metastásica, la resistencia a los fármacos y la formación de nuevos vasos sanguíneos.

Los factores impulsores responsables del crecimiento del mercado de terapias con exosomas en América del Norte son la mayor incidencia de enfermedades inflamatorias crónicas, el aumento de las actividades de investigación y desarrollo de terapias con exosomas y la financiación gubernamental para el desarrollo y la producción de terapias con exosomas. Además, el potencial de crecimiento en las economías emergentes para las terapias con exosomas y el mayor uso de terapias antienvejecimiento refuerzan el crecimiento del mercado de terapias con exosomas. Sin embargo, el aumento de los costos, las estrictas regulaciones impuestas y los riesgos observados durante el uso de las terapias con exosomas son las restricciones que pueden obstaculizar el crecimiento del mercado. Se espera que un aumento en el gasto en atención médica brinde una oportunidad lucrativa para el crecimiento del mercado. Por otro lado, el aumento de las inversiones, junto con la falta de procedimientos estandarizados para aislar exosomas, así como la no disponibilidad de la experiencia requerida, son algunos de los desafíos importantes que se espera que afecten el crecimiento del mercado.

El informe del mercado de terapias con exosomas de América del Norte proporciona detalles sobre la participación de mercado, los nuevos desarrollos y el impacto de los actores del mercado nacional y localizado, analiza las oportunidades en términos de nuevos segmentos de ingresos, cambios en las regulaciones del mercado, aprobaciones de productos, decisiones estratégicas, lanzamientos de productos, expansiones geográficas e innovaciones tecnológicas en el mercado. Para comprender el análisis y el escenario del mercado, contáctenos para obtener un resumen de analistas. Nuestro equipo lo ayudará a crear una solución de impacto en los ingresos para lograr su objetivo deseado.

Mercado de terapias con exosomas en América del NorteAlcance y tamaño del mercado de terapias con exosomas en América del Norte

El mercado de terapias con exosomas de América del Norte se clasifica en siete segmentos notables que se basan en el tipo, la fuente, la terapia, la capacidad de transporte, la aplicación, la vía de administración y el usuario final.

  • En función del tipo, el mercado de terapias con exosomas de América del Norte se segmenta en exosomas naturales y exosomas híbridos. En 2022, se espera que el segmento de exosomas naturales domine el mercado de terapias con exosomas de América del Norte debido a la presencia de material natural de los exosomas y la disponibilidad de exosomas autólogos para el tratamiento.
  • On the basis of source, the North America exosome therapeutics market is segmented into mesenchymal stem cells, blood, body fluids, urine, dendritic cells, saliva, milk, and others. In 2022, the mesenchymal stem cell segment is expected to dominate the North America exosome therapeutics market due to emerging applications of mesenchymal stem cells and expansion of the pipeline and clinical studies of mesenchymal stem cell-based products.
  • On the basis of therapy, the North America exosome therapeutics market is segmented into immunotherapy, gene therapy, and chemotherapy. In 2022, the immunotherapy segment is expected to dominate the North America exosome therapeutics market due to ease of convenience, high accuracy, and improvement in long-term survival rate.
  • On the basis of transporting capacity, the North America exosome therapeutics market is segmented into bio macromolecules and small molecules. In 2022, the bio macromolecules segment is expected to dominate the North America exosome therapeutics market due to the presence of high sensitivity, increased use of protein therapeutics to cure inflammatory disorders, cancer, and ease of availability.
  • On the basis of application, the North America exosome therapeutics market is segmented into metabolic disorders, oncology, cardiac disorders, neurology, inflammatory disorders, organ transplantation, gynecology disorders, blood disorders, and others. In 2022, the metabolic disorders segment is expected to dominate the North America exosome therapeutics market due to the increase in cases of metabolic disorders and availability of exosome therapeutics in diagnostic laboratories in the U.S. for the treatment of metabolic disorders.
  • On the basis of route of administration, the North America exosome therapeutics market is segmented into parenteral and oral. In 2022, the parenteral segment is expected to dominate the North America exosome therapeutics market due to enhanced bioavailability and rapid onset action.
  • On the basis of end user, theNorth America exosome therapeutics market is segmented into research and academic institutes, hospitals, and diagnostics centers. In 2022, the research and academic institutes segment is expected to dominate the North America exosome therapeutics market due to the rise in research and development of exosomes and support from the government in funding.

North America Exosome Therapeutics Market Country Level Analysis

North America exosome therapeutics market is analyzed, and market size information is provided by type, source, therapy, transporting capacity, application, route of administration, and end user.

The countries covered in the North America exosome therapeutics market are the U.S. and Mexico.

  • In 2021, the U.S. is expected to dominate due to the presence of the largest consumer market with high GDP. Moreover, the U.S. has the highest household spending in the world and offers trade agreements with several countries making it the largest market for consumer products, including products for exosome therapeutics due to the presence of major market players and increased technological advancement in the region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, the presence and availability of North America brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of sales channels are considered while providing forecast analysis of the country data.  

Growth Potential For Exosome Therapeutics In Emerging Economies And The Strategic Initiatives By Market Players Are Creating New Opportunities In The North America Exosome therapeutics market

North America exosome therapeutics market also provides you with detailed market analysis for every country growth in a particular industry with the exosome therapeutics sales. The impact of advancement in the exosome therapeutics and changes in regulatory scenarios with their support for the exosome therapeutics market. The data is available for the historic period 2011 to 2020.

Competitive Landscape and North America Exosome Therapeutics Market Share Analysis

North America exosome therapeutics market competitive landscape provides details by a competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width, and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus related to the exosome therapeutics market.

Some of the major companies providing the exosome therapeutics are Stem Cells Group, Exosome Sciences, AEGLE Therapeutics, Capricor Therapeutics, Avalon Globocare Corp, CODIAK, Kimera Labs, Jazz Pharmaceuticals, Inc., and EV Therapeutics, among others.

DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

The strategic initiatives by market players and new technological advancements for North America exosome therapeutics are bridging the gap for the treatment of inflammatory diseases.

For instance,

  • En abril de 2021, EV Therapeutics colaboró ​​con la Facultad de Medicina de la Universidad de Minnesota para el lanzamiento de una estrategia terapéutica basada en exosomas para el tratamiento del cáncer colorrectal. El lanzamiento de una estrategia terapéutica basada en exosomas garantizaría el uso de la estrategia terapéutica basada en exosomas en centros de diagnóstico y hospitales para el tratamiento oportuno de pacientes que padecen cáncer colorrectal.

La colaboración, las empresas conjuntas y otras estrategias de los actores del mercado están mejorando el mercado de la empresa en el mercado de terapias con exosomas, lo que también proporciona el beneficio para que una organización mejore su oferta para el mercado de terapias con exosomas de América del Norte.


SKU-

Obtenga acceso en línea al informe sobre la primera nube de inteligencia de mercado del mundo

  • Panel de análisis de datos interactivo
  • Panel de análisis de empresas para oportunidades con alto potencial de crecimiento
  • Acceso de analista de investigación para personalización y consultas
  • Análisis de la competencia con panel interactivo
  • Últimas noticias, actualizaciones y análisis de tendencias
  • Aproveche el poder del análisis de referencia para un seguimiento integral de la competencia
Solicitud de demostración

Tabla de contenido

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF THE NORTH AMERICA EXOSOME THERAPEUTICS MARKET

1.4 CURRENCY AND PRICING

1.5 LIMITATIONS

1.6 MARKETS COVERED

2 NORTH AMERICA EXOSOME THERAPEUTICS MARKET: SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 DBMR TRIPOD DATA VALIDATION MODEL

2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.6 MULTIVARIATE MODELLING

2.7 TYPE SEGMENT LIFELINE CURVE

2.8 DBMR MARKET POSITION GRID

2.9 VENDOR SHARE ANALYSIS

2.1 MARKET END USER COVERAGE GRID

2.11 SECONDARY SOURCES

2.12 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

5 PIPELINE ANALYSIS

6 NORTH AMERICA EXOSOME THERAPEUTICS MARKET: REGULATIONS

7 MARKET OVERVIEW

7.1 DRIVERS

7.1.1 RISING PREVALENCE OF CHRONIC INFLAMMATION, AUTOIMMUNE DISEASE, LYME DISEASE, AND OTHER CHRONIC DEGENERATIVE DISEASES

7.1.2 RISE IN INCIDENCE OF ONCOLOGY DISEASES

7.1.3 TECHNOLOGICAL ADVANCEMENTS IN EXOSOME THERAPEUTICS

7.1.4 RISE IN RESEARCH AND DEVELOPMENT ACTIVITIES, INVOLVED IN EXOSOME THERAPEUTICS

7.1.5 GOVERNMENT FUNDING FOR THE DEVELOPMENT AND PRODUCTION OF EXOSOME THERAPEUTICS

7.2 RESTRAINTS

7.2.1 HIGH COST ASSOCIATED WITH THE EXOSOME THERAPEUTICS

7.2.2 LACK OF AUTHENTICATION REQUIREMENTS FOR ISOLATION OF EXOSOMES

7.2.3 RISKS OBSERVED WHILE USING EXOSOME THERAPEUTICS

7.2.4 UNMET MEDICAL NEEDS

7.3 OPPORTUNITIES

7.3.1 INCREASE USE OF ANTI-AGING THERAPY

7.3.2 STRATEGIC INITIATIVES BY MARKET PLAYERS

7.3.3 RISE IN HEALTHCARE EXPENDITURE

7.3.4 AVAILABILITY OF VARIOUS EXOSOME ISOLATION AND PURIFICATION TECHNIQUES

7.3.5 PROGRESSING THERAPEUTIC VALUE OF EXOSOME

7.4 CHALLENGES

7.4.1 THE SHORTAGE OF SKILLED PROFESSIONALS REQUIRED FOR THE ISOLATION OF EXOSOME

7.4.2 LATE APPROVAL ASSOCIATED WITH PRODUCT LAUNCHES

8 IMPACT OF COVID-19 ON NORTH AMERICA EXOSOME THERAPEUTICS MARKET

8.1 IMPACT ON PRICE

8.2 IMPACT ON DEMAND

8.3 IMPACT ON SUPPLY CHAIN

8.4 STRATEGIC DECISIONS BY MANUFACTURERS

8.5 CONCLUSION

9 NORTH AMERICA EXOSOME THERAPEUTICS MARKET, BY TYPE

9.1 OVERVIEW

9.2 NATURAL EXOSOMES

9.2.1 AUTOLOGOUS EXOSOMES

9.2.2 EXOGENOUS EXOSOMES

9.3 HYBRID EXOSOMES

10 NORTH AMERICA EXOSOME THERAPEUTICS MARKET, BY SOURCE

10.1 OVERVIEW

10.2 MESENCHYMAL STEM CELLS

10.3 BLOOD

10.3.1 T-LYMPHOCYTES

10.3.2 OTHERS

10.4 BODY FLUIDS

10.4.1 AMNIOTIC FLUID

10.4.2 SEMEN

10.4.3 SYNOVIAL FLUID

10.4.4 OTHERS

10.5 URINE

10.6 DENDRITIC CELLS

10.7 SALIVA

10.8 MILK

10.9 OTHERS

11 NORTH AMERICA EXOSOME THERAPEUTICS MARKET, BY THERAPY

11.1 OVERVIEW

11.2 IMMUNOTHERAPY

11.3 GENE THERAPY

11.4 CHEMOTHERAPY

12 NORTH AMERICA EXOSOME THERAPEUTICS MARKET, BY TRANSPORTING CAPACITY

12.1 OVERVIEW

12.2 BIO MACROMOLECULES

12.2.1 NUCLEIC ACIDS

12.2.2 PROTEINS

12.2.3 PEPTIDES

12.3 SMALL MOLECULES

13 NORTH AMERICA EXOSOME THERAPEUTICS MARKET, BY APPLICATION

13.1 OVERVIEW

13.2 METABOLIC DISORDERS

13.3 ONCOLOGY

13.3.1 NON-SMALL CELL LUNG CANCER

13.3.2 BREAST CANCER

13.3.3 GASTRIC CANCER

13.3.4 HEAD AND NECK CANCER

13.3.5 OTHERS

13.4 CARDIAC DISORDERS

13.5 NEUROLOGY

13.5.1 ALZHEIMER'S DISEASE

13.5.2 PARKINSON'S DISEASE

13.5.3 OTHERS

13.6 INFLAMMATORY DISORDERS

13.7 ORGAN TRANSPLANTATION

13.8 GYNECOLOGY DISORDERS

13.9 BLOOD DISORDERS

13.1 OTHERS

14 NORTH AMERICA EXOSOME THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION

14.1 OVERVIEW

14.2 PARENTERAL

14.3 ORAL

15 NORTH AMERICA EXOSOME THERAPEUTICS MARKET, BY END USER

15.1 OVERVIEW

15.2 RESEARCH AND ACADEMIC INSTITUTES

15.3 HOSPITALS

15.4 DIAGNOSTIC CENTERS

16 NORTH AMERICA EXOSOME THERAPEUTICS MARKET, BY REGION

16.1 NORTH AMERICA

16.1.1 U.S.

16.1.2 MEXICO

17 NORTH AMERICA EXOSOME THERAPEUTICS MARKET: COMPANY LANDSCAPE

17.1 COMPANY SHARE ANALYSIS: NORTH AMERICA

18 COMPANY PROFILE

18.1 KIMERA LABS

18.1.1 COMPANY SNAPSHOT

18.1.2 COMPANY SHARE ANALYSIS

18.1.3 PRODUCT PORTFOLIO

18.1.4 RECENT DEVELOPMENTS

18.2 STEM CELLS GROUP

18.2.1 COMPANY SNAPSHOT

18.2.2 COMPANY SHARE ANALYSIS

18.2.3 PRODUCT PORTFOLIO

18.2.4 RECENT DEVELOPMENTS

18.3 AEGLE THERAPEUTICS

18.3.1 COMPANY SNAPSHOT

18.3.2 PRODUCT PORTFOLIO

18.3.3 RECENT DEVELOPMENTS

18.4 AVALON GLOBOCARE CORP.(2021)

18.4.1 COMPANY SNAPSHOT

18.4.2 REVENUE ANALYSIS

18.4.3 PRODUCT PORTFOLIO

18.4.4 RECENT DEVELOPMENTS

18.5 CAPRICOR THERAPEUTICS (2021)

18.5.1 COMPANY SNAPSHOT

18.5.2 REVENUE ANALYSIS

18.5.3 PRODUCT PORTFOLIO

18.5.4 RECENT DEVELOPMENTS

18.6 CODIAK (2021)

18.6.1 COMPANY SNAPSHOT

18.6.2 REVENUE ANALYSIS

18.6.3 PRODUCT PORTFOLIO

18.6.4 RECENT DEVELOPMENTS

18.7 EXOSOME SCIENCES (A SUBSIDIARY OF AETHLON MEDICAL) (2021)

18.7.1 COMPANY SNAPSHOT

18.7.2 REVENUE ANALYSIS

18.7.3 PRODUCT PORTFOLIO

18.7.4 RECENT DEVELOPMENTS NO RECENT DEVELOPMENTS

18.8 EXOPHARM

18.8.1 COMPANY SNAPSHOT

18.8.2 PRODUCT PORTFOLIO

18.8.3 RECENT DEVELOPMENTS

18.9 EVOX THERAPEUTICS

18.9.1 COMPANY SNAPSHOT

18.9.2 PRODUCT PORTFOLIO

18.9.3 RECENT DEVELOPMENTS

18.1 EV THERAPEUTICS

18.10.1 COMPANY SNAPSHOT

18.10.2 PRODUCT PORTFOLIO

18.10.3 RECENT DEVELOPMENTS

18.11 JAZZ PHARMACEUTICALS, INC

18.11.1 COMPANY SNAPSHOT

18.11.2 REVENUE ANALYSIS

18.11.3 PRODUCT PORTFOLIO

18.11.4 RECENT DEVELOPMENTS

18.12 RENEURON GROUP PLC

18.12.1 COMPANY SNAPSHOT

18.12.2 REVENUE ANALYSIS

18.12.3 PRODUCT PORTFOLIO

18.12.4 RECENT DEVELOPMENTS

18.13 STEM CELL MEDICINE

18.13.1 COMPANY SNAPSHOT

18.13.2 PRODUCT PORTFOLIO

18.13.3 RECENT DEVELOPMENTS

19 QUESTIONNAIRE

20 RELATED REPORTS

Lista de Tablas

TABLE 1 NORTH AMERICA EXOSOME THERAPEUTICSMARKET, PIPELINE ANALYSIS

TABLE 2 NORTH AMERICA EXOSOME THERAPEUTICS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 3 NORTH AMERICA NATURAL EXOSOMES IN EXOSOME THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 4 NORTH AMERICA NATURAL EXOSOMES IN EXOSOME THERAPEUTICS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 5 NORTH AMERICA HYBRID EXOSOMES IN EXOSOME THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 6 NORTH AMERICA EXOSOME THERAPEUTICS MARKET, BY SOURCE, 2020-2029 (USD THOUSAND)

TABLE 7 NORTH AMERICA MESENCHYMAL STEM CELLS IN EXOSOME THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 8 NORTH AMERICA BLOOD IN EXOSOME THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 9 NORTH AMERICA BLOOD IN EXOSOME THERAPEUTICS MARKET, BY SOURCE, 2020-2029 (USD THOUSAND)

TABLE 10 NORTH AMERICA BODY FLUIDS IN EXOSOME THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 11 NORTH AMERICA BLOOD IN EXOSOME THERAPEUTICS MARKET, BY SOURCE, 2020-2029 (USD THOUSAND)

TABLE 12 NORTH AMERICA URINE IN EXOSOME THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 13 NORTH AMERICA DENDRITIC CELLS IN EXOSOME THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 14 NORTH AMERICA SALIVA IN EXOSOME THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 15 NORTH AMERICA MILK IN EXOSOME THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 16 NORTH AMERICA OTHERS IN EXOSOME THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 17 NORTH AMERICA EXOSOME THERAPEUTICS MARKET, BY THERAPY, 2020-2029 (USD THOUSAND)

TABLE 18 NORTH AMERICA IMMUNOTHERAPY IN EXOSOME THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 19 NORTH AMERICA GENE THERAPY IN EXOSOME THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 20 NORTH AMERICA CHEMOTHERAPY IN EXOSOME THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 21 NORTH AMERICA EXOSOME THERAPEUTICS MARKET, BY TRANSPORTING CAPACITY, 2020-2029 (USD THOUSAND)

TABLE 22 NORTH AMERICA BIO MACROMOLECULES IN EXOSOME THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 23 NORTH AMERICA BIO MACROMOLECULES IN EXOSOME THERAPEUTICS MARKET, BY TRANSPORTING CAPACITY, 2020-2029 (USD THOUSAND)

TABLE 24 NORTH AMERICA SMALL MOLECULES IN EXOSOME THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 25 NORTH AMERICA EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2020-2029 (USD THOUSAND)

TABLE 26 NORTH AMERICA METABOLIC DISORDERS IN EXOSOME THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 27 NORTH AMERICA ONCOLOGY IN EXOSOME THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 28 NORTH AMERICA ONCOLOGY IN NORTH AMERICA EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2020-2029 (USD THOUSAND)

TABLE 29 NORTH AMERICA CARDIAC DISORDERS IN EXOSOME THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 30 NORTH AMERICA NEUROLOGY IN EXOSOME THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 31 NORTH AMERICA NEUROLOGY IN EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2020-2029 (USD THOUSAND)

TABLE 32 NORTH AMERICA INFLAMMATORY DISORDERS IN EXOSOME THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 33 NORTH AMERICA ORGAN TRANSPLANTATION IN EXOSOME THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 34 NORTH AMERICA GYNECOLOGY DISORDERS IN EXOSOME THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 35 NORTH AMERICA BLOOD DISORDERS IN EXOSOME THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 36 NORTH AMERICA OTHERS IN EXOSOME THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 37 NORTH AMERICA EXOSOME THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 38 NORTH AMERICA PARENTERAL IN EXOSOME THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 39 NORTH AMERICA ORAL IN EXOSOME THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 40 NORTH AMERICA EXOSOME THERAPEUTICS MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 41 NORTH AMERICA RESEARCH AND ACADEMIC INSTITUTES IN EXOSOME THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 42 NORTH AMERICA HOSPITALS IN EXOSOME THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 43 NORTH AMERICA DIAGNOSTIC CENTERS IN EXOSOME THERAPEUTICS MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 44 NORTH AMERICA EXOSOME THERAPEUTICS MARKET, BY COUNTRY, 2020-2029 (USD THOUSAND)

TABLE 45 NORTH AMERICA EXOSOME THERAPEUTICS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 46 NORTH AMERICA NATURAL EXOSOMES IN EXOSOME THERAPEUTICS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 47 NORTH AMERICA EXOSOME THERAPEUTICS MARKET, BY SOURCE, 2020-2029 (USD THOUSAND)

TABLE 48 NORTH AMERICA BLOOD IN EXOSOME THERAPEUTICS MARKET, BY SOURCE, 2020-2029 (USD THOUSAND)

TABLE 49 NORTH AMERICA BODY FLUIDS IN EXOSOME THERAPEUTICS MARKET, BY SOURCE, 2020-2029 (USD THOUSAND)

TABLE 50 NORTH AMERICA EXOSOME THERAPEUTICS MARKET, BY THERAPY, 2020-2029 (USD THOUSAND)

TABLE 51 NORTH AMERICA EXOSOME THERAPEUTICS MARKET, BY TRANSPORTING CAPACITY, 2020-2029 (USD THOUSAND)

TABLE 52 NORTH AMERICA BIO MACROOLECULES IN EXOSOME THERAPEUTICS MARKET, BY TRANSPORTING CAPACITY, 2020-2029 (USD THOUSAND)

TABLE 53 NORTH AMERICA EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2020-2029 (USD THOUSAND)

TABLE 54 NORTH AMERICA ONCOLOGY IN EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2020-2029 (USD THOUSAND)

TABLE 55 NORTH AMERICA NEUROLOGY IN EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2020-2029 (USD THOUSAND)

TABLE 56 NORTH AMERICA EXOSOME THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 57 NORTH AMERICA EXOSOME THERAPEUTICS MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 58 U.S. EXOSOME THERAPEUTICS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 59 U.S. NATURAL EXOSOMES IN EXOSOME THERAPEUTICS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 60 U.S. EXOSOME THERAPEUTICS MARKET, BY SOURCE, 2020-2029 (USD THOUSAND)

TABLE 61 U.S. BLOOD IN EXOSOME THERAPEUTICS MARKET, BY SOURCE, 2020-2029 (USD THOUSAND)

TABLE 62 U.S.BODY FLUIDS IN EXOSOME THERAPEUTICS MARKET, BY SOURCE, 2020-2029 (USD THOUSAND)

TABLE 63 U.S. EXOSOME THERAPEUTICS MARKET, BY THERAPY, 2020-2029 (USD THOUSAND)

TABLE 64 U.S. EXOSOME THERAPEUTICS MARKET, BY TRANSPORTING CAPACITY, 2020-2029 (USD THOUSAND)

TABLE 65 U.S. BIO MACROMOLECULES EXOSOME THERAPEUTICS MARKET, BY TRANSPORTING CAPACITY, 2020-2029 (USD THOUSAND)

TABLE 66 U.S. EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2020-2029 (USD THOUSAND)

TABLE 67 U.S. ONCOLOGY IN EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2020-2029 (USD THOUSAND)

TABLE 68 U.S. NEUROLOGY IN EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2020-2029 (USD THOUSAND)

TABLE 69 U.S. EXOSOME THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 70 U.S. EXOSOME THERAPEUTICS MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 71 MEXICO EXOSOME THERAPEUTICS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 72 MEXICO NATURAL EXOSOME IN EXOSOME THERAPEUTICS MARKET, BY TYPE, 2020-2029 (USD THOUSAND)

TABLE 73 MEXICO EXOSOME THERAPEUTICS MARKET, BY SOURCE, 2020-2029 (USD THOUSAND)

TABLE 74 MEXICO BLOOD IN EXOSOME THERAPEUTICS MARKET, BY SOURCE, 2020-2029 (USD THOUSAND)

TABLE 75 MEXICO BODY FLUIDS IN EXOSOME THERAPEUTICS MARKET, BY SOURCE, 2020-2029 (USD THOUSAND)

TABLE 76 MEXICO EXOSOME THERAPEUTICS MARKET, BY THERAPY, 2020-2029 (USD THOUSAND)

TABLE 77 MEXICO EXOSOME THERAPEUTICS MARKET, BY TRANSPORTING CAPACITY, 2020-2029 (USD THOUSAND)

TABLE 78 MEXICO BIO MACROMOLECULES IN EXOSOME THERAPEUTICS MARKET, BY TRANSPORTING CAPACITY, 2020-2029 (USD THOUSAND)

TABLE 79 MEXICO EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2020-2029 (USD THOUSAND)

TABLE 80 MEXICO ONCOLOGY IN EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2020-2029 (USD THOUSAND)

TABLE 81 MEXICO NEUROLOGY IN EXOSOME THERAPEUTICS MARKET, BY APPLICATION, 2020-2029 (USD THOUSAND)

TABLE 82 MEXICO EXOSOME THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 83 MEXICO EXOSOME THERAPEUTICS MARKET, BY END USER, 2020-2029 (USD THOUSAND)

Lista de figuras

FIGURE 1 NORTH AMERICA EXOSOME THERAPEUTICS MARKET: SEGMENTATION

FIGURE 2 NORTH AMERICA EXOSOME THERAPEUTICS MARKET: DATA TRIANGULATION

FIGURE 3 NORTH AMERICA EXOSOME THERAPEUTICS MARKET: DROC ANALYSIS

FIGURE 4 NORTH AMERICA EXOSOME THERAPEUTICS MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS

FIGURE 5 NORTH AMERICA EXOSOME THERAPEUTICS MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 NORTH AMERICA EXOSOME THERAPEUTICS MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 NORTH AMERICA EXOSOME THERAPEUTICS MARKET: DBMR POSITION GRID

FIGURE 8 NORTH AMERICA EXOSOME THERAPEUTICS MARKET: VENDOR SHARE ANALYSIS

FIGURE 9 NORTH AMERICA EXOSOME THERAPEUTICS MARKET: END USER COVERAGE GRID

FIGURE 10 NORTH AMERICA EXOSOME THERAPEUTICS MARKET: SEGMENTATION

FIGURE 11 THE INCREASED PREVALENCE OF AUTOIMMUNE DISORDERS, LYME DISEASES, INCIDENCE OF CANCER AND RISE IN TECHNOLOGICAL ADVANCEMENTS IS EXPECTED TO DRIVE THE NORTH AMERICA EXOSOME THERAPEUTICS MARKET FROM 2022 TO 2029

FIGURE 12 TYPE SEGMENT IS EXPECTED TO HAVE THE LARGEST SHARE OF THE NORTH AMERICA EXOSOME THERAPEUTICS MARKET IN 2022 & 2029

FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF NORTH AMERICA EXOSOME THERAPEUTICS MARKET

FIGURE 14 THE PREVALENCE OF MULTIPLE SCLEROSIS IN WORLD HEALTH ORGANISATION (WHO) REGIONS IN 2020.

FIGURE 15 INCIDENCE RATE OF CANCER IN AUSTRALIA AND OTHER COUNTRIES (2020)

FIGURE 16 NORTH AMERICA EXOSOME THERAPEUTICS MARKET: BY TYPE, 2021

FIGURE 17 NORTH AMERICA EXOSOME THERAPEUTICS MARKET: BY TYPE, 2020-2029 (USD THOUSAND)

FIGURE 18 NORTH AMERICA EXOSOME THERAPEUTICS MARKET: BY TYPE, CAGR (2022-2029)

FIGURE 19 NORTH AMERICA EXOSOME THERAPEUTICS MARKET: BY TYPE, LIFELINE CURVE

FIGURE 20 NORTH AMERICA EXOSOME THERAPEUTICS MARKET: BY SOURCE, 2021

FIGURE 21 NORTH AMERICA EXOSOME THERAPEUTICS MARKET: BY SOURCE, 2020-2029 (USD THOUSAND)

FIGURE 22 NORTH AMERICA EXOSOME THERAPEUTICS MARKET: BY SOURCE, CAGR (2022-2029)

FIGURE 23 NORTH AMERICA EXOSOME THERAPEUTICS MARKET: BY SOURCE, LIFELINE CURVE

FIGURE 24 NORTH AMERICA EXOSOME THERAPEUTICS MARKET: BY THERAPY, 2021

FIGURE 25 NORTH AMERICA EXOSOME THERAPEUTICS MARKET: BY THERAPY, 2020-2029 (USD THOUSAND)

FIGURE 26 NORTH AMERICA EXOSOME THERAPEUTICS MARKET: BY THERAPY, CAGR (2022-2029)

FIGURE 27 NORTH AMERICA EXOSOME THERAPEUTICS MARKET: BY THERAPY, LIFELINE CURVE

FIGURE 28 NORTH AMERICA EXOSOME THERAPEUTICS MARKET: BY TRANSPORTING CAPACITY, 2021

FIGURE 29 NORTH AMERICA EXOSOME THERAPEUTICS MARKET: BY TRANSPORTING CAPACITY, 2020-2029 (USD THOUSAND)

FIGURE 30 NORTH AMERICA EXOSOME THERAPEUTICS MARKET: BY TRANSPORTING CAPACITY, CAGR (2022-2029)

FIGURE 31 NORTH AMERICA EXOSOME THERAPEUTICS MARKET: BY TRANSPORTING CAPACITY, LIFELINE CURVE

FIGURE 32 NORTH AMERICA EXOSOME THERAPEUTICS MARKET: BY APPLICATION, 2021

FIGURE 33 NORTH AMERICA EXOSOME THERAPEUTICS MARKET: BY APPLICATION, 2020-2029 (USD THOUSAND)

FIGURE 34 NORTH AMERICA EXOSOME THERAPEUTICS MARKET: BY APPLICATION, CAGR (2022-2029)

FIGURE 35 NORTH AMERICA EXOSOME THERAPEUTICS MARKET: BY APPLICATION, LIFELINE CURVE

FIGURE 36 NORTH AMERICA EXOSOME THERAPEUTICS MARKET: BY ROUTE OF ADMINISTRATION, 2021

FIGURE 37 NORTH AMERICA EXOSOME THERAPEUTICS MARKET: BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

FIGURE 38 NORTH AMERICA EXOSOME THERAPEUTICS MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2022-2029)

FIGURE 39 NORTH AMERICA EXOSOME THERAPEUTICS MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE

FIGURE 40 NORTH AMERICA EXOSOME THERAPEUTICS MARKET: BY END USER, 2021

FIGURE 41 NORTH AMERICA EXOSOME THERAPEUTICS MARKET: BY END USER, 2020-2029 (USD THOUSAND)

FIGURE 42 NORTH AMERICA EXOSOME THERAPEUTICS MARKET: BY END USER, CAGR (2022-2029)

FIGURE 43 NORTH AMERICA EXOSOME THERAPEUTICS MARKET: BY END USER, LIFELINE CURVE

FIGURE 44 NORTH AMERICA EXOSOME THERAPEUTICS MARKET: SNAPSHOT (2021)

FIGURE 45 NORTH AMERICA EXOSOME THERAPEUTICS MARKET: BY COUNTRY (2021)

FIGURE 46 NORTH AMERICA EXOSOME THERAPEUTICS MARKET: BY COUNTRY (2022 & 2029)

FIGURE 47 NORTH AMERICA EXOSOME THERAPEUTICS MARKET: BY COUNTRY (2021 & 2029)

FIGURE 48 NORTH AMERICA EXOSOME THERAPEUTICS MARKET: BY TYPE (2022-2029)

FIGURE 49 NORTH AMERICA EXOSOME THERAPEUTICS MARKET: COMPANY SHARE 2021 (%)

Ver información detallada Right Arrow

Metodología de investigación

La recopilación de datos y el análisis del año base se realizan utilizando módulos de recopilación de datos con muestras de gran tamaño. La etapa incluye la obtención de información de mercado o datos relacionados a través de varias fuentes y estrategias. Incluye el examen y la planificación de todos los datos adquiridos del pasado con antelación. Asimismo, abarca el examen de las inconsistencias de información observadas en diferentes fuentes de información. Los datos de mercado se analizan y estiman utilizando modelos estadísticos y coherentes de mercado. Además, el análisis de la participación de mercado y el análisis de tendencias clave son los principales factores de éxito en el informe de mercado. Para obtener más información, solicite una llamada de un analista o envíe su consulta.

La metodología de investigación clave utilizada por el equipo de investigación de DBMR es la triangulación de datos, que implica la extracción de datos, el análisis del impacto de las variables de datos en el mercado y la validación primaria (experto en la industria). Los modelos de datos incluyen cuadrícula de posicionamiento de proveedores, análisis de línea de tiempo de mercado, descripción general y guía del mercado, cuadrícula de posicionamiento de la empresa, análisis de patentes, análisis de precios, análisis de participación de mercado de la empresa, estándares de medición, análisis global versus regional y de participación de proveedores. Para obtener más información sobre la metodología de investigación, envíe una consulta para hablar con nuestros expertos de la industria.

Personalización disponible

Data Bridge Market Research es líder en investigación formativa avanzada. Nos enorgullecemos de brindar servicios a nuestros clientes existentes y nuevos con datos y análisis que coinciden y se adaptan a sus objetivos. El informe se puede personalizar para incluir análisis de tendencias de precios de marcas objetivo, comprensión del mercado de países adicionales (solicite la lista de países), datos de resultados de ensayos clínicos, revisión de literatura, análisis de mercado renovado y base de productos. El análisis de mercado de competidores objetivo se puede analizar desde análisis basados ​​en tecnología hasta estrategias de cartera de mercado. Podemos agregar tantos competidores sobre los que necesite datos en el formato y estilo de datos que esté buscando. Nuestro equipo de analistas también puede proporcionarle datos en archivos de Excel sin procesar, tablas dinámicas (libro de datos) o puede ayudarlo a crear presentaciones a partir de los conjuntos de datos disponibles en el informe.

Preguntas frecuentes

The market is segmented based on North America Exosome Therapeutics Market, By Type (Natural Exosomes, Hybrid Exosomes), Source (Mesenchymal Stem Cell, Blood, Body Fluids, Urine, Dendritic Cells, Saliva, Milk, and Others), Source (T-Lymphocytes and Others), Therapy (Immunotherapy, Gene Therapy, Chemotherapy), Transporting Capacity (Bio Macromolecules and Small Molecules), Application (Metabolic Disorders, Oncology, Cardiac Disorders, Neurology, Inflammatory Disorders, Organ Transplantation, Gynecology Disorders, Blood Disorders, and Others), Route of Administration (Parenteral, Oral), End User (Research and Academic Institutes, Hospitals and Diagnostic Centers), By Country (U.S. & Mexico), Market Trends and Forecast to 2028.   .
The North America Exosome Therapeutic Market size was valued at USD 327.63 USD Thousand in 2020.
The North America Exosome Therapeutic Market is projected to grow at a CAGR of 17.2% during the forecast period of 2021 to 2028.